Cediranib (AZD2171) in patients with advanced hepatocellular carcinoma: A phase II north central cancer treatment group clinical trial

Steven Robert Alberts, Tom R. Fitch, George P. Kim, Bruce W. Morlan, Shaker R. Dakhil, Howard M. Gross, Suresh Nair

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Objectives: Vascular endothelial growth factor has been shown to be overexpressed in several studies of hepatocellular carcinoma (HCC). Cediranib is a potent inhibitor of vascular endothelial growth factor signaling. We assessed the efficacy and toxicity of cediranib in patients with HCC. Methods: Twenty-eight patients with unresectable or metastatic HCC were enrolled in this study. Patients received 45 mg of cediranib orally, once daily, for 28-day cycles. The primary objective of this phase II study was to assess 6-month survival. Secondary objectives were to assess tumor response, time to progression, and toxicity. Results: All 28 patients were evaluable for efficacy outcomes. Twelve patients (42.9%) survived 6 months, 15 (53.6%) died within 6 months, and 1 (3.6%) was lost to follow-up before 6 months. The median overall survival was 5.8 months (95% confidence interval, 3.4-7.3 mo). No patients experienced confirmed response. The median time to progression was 2.8 months (95% confidence interval, 2.3-4.4 mo). Twenty-six patients (93%) experienced a grade 3+ adverse event with the most common adverse event s being fatigue (46%), anorexia (25%), hypertension (21%), and elevated alanine aminotransferase (18%). Conclusions: Owing to the toxicity, cediranib at this dose and schedule is not an effective treatment in patients with unresectable or metastatic HCC.

Original languageEnglish (US)
Pages (from-to)329-333
Number of pages5
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume35
Issue number4
DOIs
StatePublished - Aug 2012

Fingerprint

Hepatocellular Carcinoma
Clinical Trials
Neoplasms
Therapeutics
Vascular Endothelial Growth Factor A
Confidence Intervals
Survival
cediranib
Lost to Follow-Up
Anorexia
Alanine Transaminase
Reaction Time
Fatigue
Appointments and Schedules
Hypertension

Keywords

  • AZD2171
  • cediranib
  • hepatocellular carcinoma
  • phase II
  • VEGF

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Cediranib (AZD2171) in patients with advanced hepatocellular carcinoma : A phase II north central cancer treatment group clinical trial. / Alberts, Steven Robert; Fitch, Tom R.; Kim, George P.; Morlan, Bruce W.; Dakhil, Shaker R.; Gross, Howard M.; Nair, Suresh.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 35, No. 4, 08.2012, p. 329-333.

Research output: Contribution to journalArticle

Alberts, Steven Robert ; Fitch, Tom R. ; Kim, George P. ; Morlan, Bruce W. ; Dakhil, Shaker R. ; Gross, Howard M. ; Nair, Suresh. / Cediranib (AZD2171) in patients with advanced hepatocellular carcinoma : A phase II north central cancer treatment group clinical trial. In: American Journal of Clinical Oncology: Cancer Clinical Trials. 2012 ; Vol. 35, No. 4. pp. 329-333.
@article{b3a9d7d05c57440d9482ea15e2139d70,
title = "Cediranib (AZD2171) in patients with advanced hepatocellular carcinoma: A phase II north central cancer treatment group clinical trial",
abstract = "Objectives: Vascular endothelial growth factor has been shown to be overexpressed in several studies of hepatocellular carcinoma (HCC). Cediranib is a potent inhibitor of vascular endothelial growth factor signaling. We assessed the efficacy and toxicity of cediranib in patients with HCC. Methods: Twenty-eight patients with unresectable or metastatic HCC were enrolled in this study. Patients received 45 mg of cediranib orally, once daily, for 28-day cycles. The primary objective of this phase II study was to assess 6-month survival. Secondary objectives were to assess tumor response, time to progression, and toxicity. Results: All 28 patients were evaluable for efficacy outcomes. Twelve patients (42.9{\%}) survived 6 months, 15 (53.6{\%}) died within 6 months, and 1 (3.6{\%}) was lost to follow-up before 6 months. The median overall survival was 5.8 months (95{\%} confidence interval, 3.4-7.3 mo). No patients experienced confirmed response. The median time to progression was 2.8 months (95{\%} confidence interval, 2.3-4.4 mo). Twenty-six patients (93{\%}) experienced a grade 3+ adverse event with the most common adverse event s being fatigue (46{\%}), anorexia (25{\%}), hypertension (21{\%}), and elevated alanine aminotransferase (18{\%}). Conclusions: Owing to the toxicity, cediranib at this dose and schedule is not an effective treatment in patients with unresectable or metastatic HCC.",
keywords = "AZD2171, cediranib, hepatocellular carcinoma, phase II, VEGF",
author = "Alberts, {Steven Robert} and Fitch, {Tom R.} and Kim, {George P.} and Morlan, {Bruce W.} and Dakhil, {Shaker R.} and Gross, {Howard M.} and Suresh Nair",
year = "2012",
month = "8",
doi = "10.1097/COC.0b013e3182118cdf",
language = "English (US)",
volume = "35",
pages = "329--333",
journal = "American Journal of Clinical Oncology: Cancer Clinical Trials",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Cediranib (AZD2171) in patients with advanced hepatocellular carcinoma

T2 - A phase II north central cancer treatment group clinical trial

AU - Alberts, Steven Robert

AU - Fitch, Tom R.

AU - Kim, George P.

AU - Morlan, Bruce W.

AU - Dakhil, Shaker R.

AU - Gross, Howard M.

AU - Nair, Suresh

PY - 2012/8

Y1 - 2012/8

N2 - Objectives: Vascular endothelial growth factor has been shown to be overexpressed in several studies of hepatocellular carcinoma (HCC). Cediranib is a potent inhibitor of vascular endothelial growth factor signaling. We assessed the efficacy and toxicity of cediranib in patients with HCC. Methods: Twenty-eight patients with unresectable or metastatic HCC were enrolled in this study. Patients received 45 mg of cediranib orally, once daily, for 28-day cycles. The primary objective of this phase II study was to assess 6-month survival. Secondary objectives were to assess tumor response, time to progression, and toxicity. Results: All 28 patients were evaluable for efficacy outcomes. Twelve patients (42.9%) survived 6 months, 15 (53.6%) died within 6 months, and 1 (3.6%) was lost to follow-up before 6 months. The median overall survival was 5.8 months (95% confidence interval, 3.4-7.3 mo). No patients experienced confirmed response. The median time to progression was 2.8 months (95% confidence interval, 2.3-4.4 mo). Twenty-six patients (93%) experienced a grade 3+ adverse event with the most common adverse event s being fatigue (46%), anorexia (25%), hypertension (21%), and elevated alanine aminotransferase (18%). Conclusions: Owing to the toxicity, cediranib at this dose and schedule is not an effective treatment in patients with unresectable or metastatic HCC.

AB - Objectives: Vascular endothelial growth factor has been shown to be overexpressed in several studies of hepatocellular carcinoma (HCC). Cediranib is a potent inhibitor of vascular endothelial growth factor signaling. We assessed the efficacy and toxicity of cediranib in patients with HCC. Methods: Twenty-eight patients with unresectable or metastatic HCC were enrolled in this study. Patients received 45 mg of cediranib orally, once daily, for 28-day cycles. The primary objective of this phase II study was to assess 6-month survival. Secondary objectives were to assess tumor response, time to progression, and toxicity. Results: All 28 patients were evaluable for efficacy outcomes. Twelve patients (42.9%) survived 6 months, 15 (53.6%) died within 6 months, and 1 (3.6%) was lost to follow-up before 6 months. The median overall survival was 5.8 months (95% confidence interval, 3.4-7.3 mo). No patients experienced confirmed response. The median time to progression was 2.8 months (95% confidence interval, 2.3-4.4 mo). Twenty-six patients (93%) experienced a grade 3+ adverse event with the most common adverse event s being fatigue (46%), anorexia (25%), hypertension (21%), and elevated alanine aminotransferase (18%). Conclusions: Owing to the toxicity, cediranib at this dose and schedule is not an effective treatment in patients with unresectable or metastatic HCC.

KW - AZD2171

KW - cediranib

KW - hepatocellular carcinoma

KW - phase II

KW - VEGF

UR - http://www.scopus.com/inward/record.url?scp=84864348077&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864348077&partnerID=8YFLogxK

U2 - 10.1097/COC.0b013e3182118cdf

DO - 10.1097/COC.0b013e3182118cdf

M3 - Article

C2 - 21422991

AN - SCOPUS:84864348077

VL - 35

SP - 329

EP - 333

JO - American Journal of Clinical Oncology: Cancer Clinical Trials

JF - American Journal of Clinical Oncology: Cancer Clinical Trials

SN - 0277-3732

IS - 4

ER -